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Recently, several pharmaceutical companies have been
shown to have withheld negative clinical trial results
from the public. These incidents have resulted in a
concerted global effort to register all trials at inception,
so that all subsequent results can be tracked regardless
of whether they are positive or negative. These trial
registration policies have been driven in large part by
concern about the pharmaceutical sector. The medical
device industry is much smaller, and different from the
pharmaceutical industry in some fundamental ways.
This paper examines the issues surrounding registra-
tion of device trials and argues that these differences
with pharmaceutical should not exempt device trials
from registration.
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INTRODUCTION
When most clinicians and patients think of the biomedical
industry, it is “Big Pharma” that comes to mind—large
multinational pharmaceutical companies that make and sell
prescription drugs. The pharmaceutical industry’s annual
revenues, $600 billion worldwide, are triple those of medical
devices. The pharmaceutical industry has a considerable
presence in the media, and also on Capitol Hill, where the
Pharmaceutical Research and Manufacturers of America
(PhRMA) is widely considered to be 1 of the most powerful
lobbying organizations in the United States. In contrast, its
fellow industry sectors, biotechnology and medical devices,
have a lower profile in public and in the professional medical
world.
One consequence of this differential attention toward the
pharmaceutical industry is that public policy affecting the
whole biomedical industry may sometimes be disproportion-
ately driven by the features and concerns of the pharmaceu-
tical sector. For example, several pharmaceutical companies
have recently been shown to have withheld clinical trial results
that were unfavorable to their commercial interests. GlaxoS-
mithKline (GSK) withheld data on adolescent suicide ideation
with paroxetine (Paxil).
1 Merck withheld data on cardiovascu-
lar risk from rofecoxib (Vioxx).
2 The legal settlement in August
2004 between New York Attorney General Eliot Spitzer and
GSK over the Paxil scandal reflected the seriousness of
withholding trial data, and the International Committee of
Medical Journal Editors (ICMJE) followed up with a bold move
to require that trials must be registered at inception for the
results to be considered for publication.
3 In the last 2 years, a
flurry of state and national legislation have been introduced
calling for mandatory clinical trial registration, and the World
Health Organization (WHO) is establishing international norms
and standards to coordinate the global effort to restore public
trust in clinical trials through trial registration.
Because the inciting scandals were originally from the
pharmaceutical industry, a perception has been that the
problem (withheld data) and the solution (mandatory trial
registration) apply only to pharmaceutical trials. The device
industry argues that fundamental differences between the
pharmaceutical and device industries should be reflected in a
differentiated regulatory approach.
4, 5 It is thus worth review-
ing the differences between the pharmaceutical and device
industries, and to consider whether device trials should be
exempt from or fall under different trial registration policies
than pharmaceutical trials.
DIFFERENCES BETWEEN THE MEDICAL DEVICE
AND PHARMACEUTICAL INDUSTRIES
The medical device and pharmaceutical industries differ in
many respects, including size, degree of consolidation, product
development cycle, product lifecycle, and their scientific,
clinical, and regulatory environments (Table 1). These differ-
ences, while true today, are in flux as the biomedical products
industry is changing. Drug-device hybrid products such as
drug-eluting stents are blurring the line between devices and
pharmaceuticals, pharmaceutical firms are increasingly merg-
ing with biotechnology firms in an effort to bolster product
pipelines,
6 and the underlying model of pharmaceutical in-
dustry innovation appears to be shifting away from blockbust-
er drugs toward an as-yet-undefined model.
7
The pharmaceutical industry is a mature, global industry
that is comprised primarily of large multinationals. The device
industry is younger, less global, and comprised of a few large
companies and many more small- to medium-sized compa-
nies. The pharmaceutical industry relies on blockbuster drugs
(defined as over $1 billion in global annual revenues) for
profits.
7 Devices are often designed and targeted for markets
of less than $100 million in annual revenue. The pharmaceu-
tical industry often speaks through PhRMA, their American
trade association, as well as the International Federation of
64Pharmaceutical Manufacturers & Associations (IFPMA). The
device industry is represented by AdvaMed in the United
States, MEDEC in Canada, and Eucomed in Europe.
In pharmaceuticals, the traditional development and inno-
vation process centers on using pharmacology and chemistry
to develop a drug—a stable, unchanging molecular entity—
that is almost always patented before it undergoes clinical
testing. Product development involves years of trials to dem-
onstrate and prove quality, safety, and efficacy for broad
populations. Once the product is approved, the company
generally has years of market exclusivity in which to recoup
costs and generate profits. In contrast, the development and
innovation process for devices draws on a wide range of
disciplines and technologies, including electrical, mechanical,
chemical, and bio-engineering. Patents provide less protection
than for pharmaceuticals, because simple design or engineer-
ing changes can circumvent a patent. Product development
occurs in short iterative cycles each lasting months, with
incremental improvements being continuously introduced
even during product evaluation. Once on the market, the
investment recovery period is comparatively shorter, as little as
18 months in contrast to years for pharmaceuticals.
The regulatory framework for pharmaceuticals and devices
also differ substantially. The FDA approves new molecular
entities only if clinical data are submitted that demonstrate
safety and efficacy. For devices, FDA approval is based on the
device’s risk classification and may not require any clinical
data at all.
8 Class I devices (e.g., bandages, bedpans) are low-
risk and are governed by “general controls” on packaging,
labeling, and the like. Class II devices are moderate-risk (e.g.,
infusion pumps) and are governed by “special controls” such
as mandatory performance standards and requirements for
post-market surveillance. Class III devices are high-risk
devices (e.g., heart valves) or devices that are not “substantially
equivalent” to a similar device already on the market. Class III
devices require premarket approval through the submission of
clinical and nonclinical data (e.g., design and manufacturing
data) to demonstrate safety and effectiveness, but not neces-
sarily efficacy. Overall, the regulatory requirements for dem-
onstrating clinical benefit are less stringent for devices than for
pharmaceuticals.
Another distinguishing feature between the device and
pharmaceutical industries is that devices are more often
developed in closer collaboration with clinicians and are then
marketed to them with less reliance on published results of
clinical trials. This marketing approach has allowed smaller
companies to succeed even if they lack the ability to run large
randomized trials. However, as payers increasingly look for
evidence of efficacy to support coverage decisions, the demand
for clinical trials on devices is increasing,
9 and therefore also
the relevance of trial registration to the device industry.
5
TRIAL REGISTRATION
The idea of trial registration, mired for decades in academic
backwaters, finally became “irresistible”
10 as the public real-
ized the harm from withholding negative clinical trial results.
To prevent such selective reporting of results, all trials
worldwide should be publicly registered and uniquely identi-
fied in open access registers, such that all results, whether
“good” or “bad,” can be tracked down.
11 Trial registration is a
necessary prerequisite to ensuring an unbiased evidence base
for patient care and public policy.
12
Recognizing the need for global coordination of trial regis-
tration, the World Health Organization launched the Interna-
tional Clinical Trials Registry Platform in 2005
13 to establish a
coordinated network of international trial registers. This
network is now operational and includes national and inter-
national trial registers. Each participating register offers open
access to a standard set of 20 trial-registration data items
describing a trial’s basic design (Table 2). Trials are to be
registered by the Responsible Registrant (either the Principal
Investigator or the Primary Sponsor
14) and the trial should be
registered once and only once in the network. The WHO
Registry Platform is also developing norms and standards for
a minimum set of results to be reported for all registered trials.
INDUSTRY CONCERNS REGARDING TRIAL
REGISTRATION
Industry voiced 2 major concerns regarding trial registration.
The first concern was whether early trials, commonly known
as Phase I trials, should be registered. The second was whether
trial registration information should be fully disclosed at the
time of registration. Both concerns reflect the tension between
protecting competitive advantage for industry and the scien-
tific and ethical responsibilities to trial participants and public
health.
Table 1. Summary Differences Between the Pharmaceutical and
Device Industries
Devices industry Pharmaceutical industry
Industry characteristics
Annual global revenue ∼US$200
billion
Annual global revenue
∼ US$600 billion
Comprised mostly of small- to
medium-sized companies
Comprised primarily of large
multinationals
Younger, more localized industry Mature global industry
Represented by AdvaMed,
MEDEC, EucoMed
Represented by PhRMA*,
IFPMA†
Products
Draws upon mechanical,
electrical, materials, and
bio-engineering, now
expanding to biotechnology, etc.
Traditionally centered on
pharmacology and chemistry,
now expanding to
biotechnology, etc.
Mechanical or electrical devices,
or both, to replace or augment
body parts and/or function
with more localized effects
Stable, unchanging molecular
entities with systemic effects
Product development
Short iterative cycles each lasting
months, to demonstrate safety,
and effectiveness
Years of clinical trials to
demonstrate safety and efficacy
Continuous incremental
improvements introduced
during product evaluation
Product essentially unchanged
during evaluation
Annual revenue target usually
<$100 million
Blockbuster annual revenue
target >$1 billion
Investment recovery period as
short as 18 months
Years of market exclusivity
Less reliance on publications of
clinicaltrialresults formarketing
Marketing approach relies more
heavily on clinical trials and
publications
*Pharmaceutical Research and Manufacturers of America
†International Federation of Pharmaceutical Manufacturers & Associations
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The pharmaceutical industry has argued against the registra-
tion of early-phase studies because these “exploratory” studies
are used only “to plan the conduct of confirmatory clinical
trials”.
15 T h ei n d u s t r yc l a i m st h a tt hese non-hypothesis-
testing trials “do not generate data which are used to support
clinical claims or recommendations for use” and therefore offer
little evidentiary value to the scientific and clinical communi-
ties. They further claim that registration of early-phase trials
would impede innovation because public release of the 20
registration data items would unfairly provide their competi-
tors with development plans and would result in the loss of
competitive advantage. In addition to the arguments advanced
by the pharmaceutical industry, the device industry also
claims that early-phase studies of devices are particularly
non-informative for public health because devices undergo
such frequent, incremental improvements that the devices
tested in early-phase studies are often quite dissimilar to the
marketed product
4. This situation differs from typical drug
development where the compound is essentially unchanged
from early- to late-phase testing.
Table 2. World Health Organization Trial Registration Data Set
Item Definition/Explanation
1. Primary Register and Trial ID # Name of trial register in which this trial was first registered (the trial’s “Primary Register”), and the unique ID
number assigned by the Primary Register.
2. Date of Registration in Primary
Register
Date when trial was officially registered in the Primary Register YYYY/MM/DD.
3. Secondary ID#s Other identifying numbers and issuing authorities besides the Primary Register, if any. This includes the
sponsor name and sponsor-issued trial number (e.g., protocol number) if available, and other trial registers
that have issued an ID number to this trial.
4. Source(s) of Monetary or Material
Support
Major source(s) of monetary or material support for the trial (e.g., funding agency, foundation, company).
5. Primary Sponsor The individual, organisation, group, or other legal person taking on responsibility for securing the
arrangements to initiate and/or manage a study (including arrangements to ensure that the design of
the study meets appropriate standards and to ensure appropriate conduct and reporting). The primary
sponsor is normally the main applicant for regulatory authorization to begin the study. It may or may not
be the main funder.
6. Secondary Sponsor(s) Additional individuals, organisations or other legal persons, if any, that have agreed with the primary sponsor to
take on responsibilities of sponsorship.
7. Contact for Public Queries Email address, telephone number, or address of the contact who will respond to general queries, including
information about current recruitment status
8. Contact for Scientific Queries Emailaddress,telephonenumber,orpostaladdress,andaffiliationofthepersontocontactforscientificinquiries
about the trial (e.g., principal investigator, medical director employed by the sponsor). For a multicenter study,
the contact should be for the lead principal investigator or overall scientific director.
9. Public Title Title intended for the lay public in easily understood language.
10. Scientific Title Scientific title of the study as it appears in the protocol submitted for funding and ethical review, including the
trial acronym if available.
11. Countries of
Recruitment
The countries from which participants will be, are intended to be, or have been recruited
12. Health Condition(s) or Problem
(s) Studied
Primary health condition(s) or problem(s) studied (e.g., depression, breast cancer, medication error).
13. Intervention(s) The specific name of the intervention(s) and the comparator/control(s) being studied. The International Non-
Proprietary Name should be used if possible (not brand/trade names). For an unregistered drug, the
generic name, chemical name, or company serial number is acceptable. The control intervention(s) is/are
the interventions against which the study intervention is evaluated (e.g., placebo, no treatment, active
control). If an active control is used, the name(s) of that intervention, or “placebo” or “no treatment” should
be provided as applicable. For each intervention, other intervention details should also be described as
applicable (dose, duration, mode of administration, etc)
14. Key Inclusion and Exclusion
Criteria
Inclusion and exclusion criteria for participant selection, including age and sex.
15. Study Type A single arm study is one in which all participants are given the same intervention. Trials in which
participants are assigned to receive 1 of 2 or more interventions are NOT single arm studies.Crossover
trials are NOT single arm studies. A trial is “randomized” if participants are/were assigned to intervention
groups using a method based on chance (e.g., random number table, random computer-generated
sequence, minimization).
16. Date of First Enrollment Anticipated or actual date of enrollment of the first participant (YYYY/MM).
17. Target Sample Size Number of participants that this trial plans to or had planned to enroll
18. Recruitment Status Recruitment status of this trial (Pending, Active, Temporary halt, Closed)
19. Primary Outcome(s) Outcomes are events, variables, or experiences that trial investigators measure because it is believed that
they may be influenced by the intervention. The Primary Outcome should be the outcome used in sample
size calculations, or the main outcome(s) used to determine the effects of the intervention(s).
20. Secondary Outcomes Secondary outcomes are events, variables, or experiences of secondary interest or that are measured at
timepoints of secondary interest. A secondary outcome may involve the same event, variable, or experience
as the primary outcome, but measured at time points other than those of primary interest (e.g., primary
outcome: all-cause mortality at 5 years; secondary outcome: all-cause mortality at 1 year, 3 years), or may
involve a different event, variable, or experience altogether (e.g., primary outcome: all-cause mortality at
5 years; secondary outcome: hospitalization rate at 5 years).
Adapted from the WHO International Clinical Trials Registry Platform, http://www.who.int/ictrp/data_set/en/index1.html.
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the concerns of other stakeholders in clinical trials like the
Ottawa Group
16 that advocated full and complete disclosure of
detailed trial informtion. Therefore, WHO convened a safe-
harbor consultation held in Geneva in 2005, with representa-
tives from the pharmaceutical, device, and biotechnology
industries; patient and consumer groups; medical journal
editors; ethicists; regulatory officials; and scientists to explore
these concerns and to define a common international ap-
proach to trial registration. WHO concluded that the claimed
threats to proprietary and commercial interests were uncon-
vincing and did not outweigh the benefits of early phase trial
registration.
16 These benefits include the provision of design
information that can inform the planning of new trials and
help reduce unnecessary duplication. Although the ICMJE
originally required the registration of only late-phase “clinically
directive” trials, they have since revised their position to
require the registration of early- as well as late-phase studies.
17
The implementation of early-phase trial registration is,
however, undoubtedly challenging. It is unknown how many
early-phase trials there are—probably thousands worldwide
each enrolling small numbers of participants. It is not yet clear
that the 20-item data set, originally designed for late-phase
studies, is fully appropriate for early studies, or for device
studies in particular. It must also be acknowledged that late-
phase randomized studies are more likely to yield “clinically
directive” evidence than early-phase studies so that practically
speaking, registration policies might focus on late-phase,
“non-exploratory” or “hypothesis-testing” trials. Furthermore,
there exist methodological concerns about the appropriateness
of standard clinical trial designs for the very iterative nature of
early-phase device testing.
9 It may be reasonable to focus
initial efforts in registration of early-phase trials to the
pharmaceutical rather than the devices industry.
Disclosure Timing of the Registration Data Set
The other major concern over trial registration officially voiced
by both the pharmaceutical and devices industry was the
timing of public access to 5 commercially “sensitive” registra-
tion data items
4,18: (1) official scientific title of the study; (2)
intervention name(s); (3) target sample size; (4) primary
outcome; and (5) key secondary outcomes. To protect compet-
itive advantage, the industries proposed withholding these 5
data items from public disclosure until the sponsor (i.e., the
company) determines that “the information is no longer
commercially sensitive”.
18 This issue of disclosure timing was
also addressed at the safe-harbor consultation that the WHO
held in Geneva in 2005. Again, WHO found the claim that full
and immediate disclosure of registration data would threaten
the industry’s competitive health to be unconvincing, and that
these threats would not in any case outweigh the benefits to
the public good of immediate disclosure.
16
In this matter of disclosure timing of registration informa-
tion, none of the differences between the pharmaceutical and
device industries were material. AdvaMed argued that because
the device industry has less patent protection, the “forced
disclosure of intellectual property” from trial registration will
be particularly injurious.
4 However, as in the pharmaceutical
industry, the 5 “sensitive” items are often already available to
competitors through fee-based commercial intelligence ser-
vices or through patient consent forms that can be obtained
publicly. If competitors within the industry already have access
to the 5 “sensitive” items, then there is no case for limiting
public access to them.
ETHICS AND POLICY ISSUES IN DEVICE TRIAL
REPORTING
Experimenting on human beings is a serious matter. In
enunciating the core ethical principles on human research,
the Declaration of Helsinki states explicitly that “the design of
all studies should be publicly available”.
19 Trial registration
aims to meet this ethical duty by making public the design and
existence of all trials. No commercial sector can claim exemp-
tion from this duty. This duty extends even to small early-
phase trials as every trial participant, whether as 1 of 6 or
6,000 participants, deserves the same considerations under
the Declaration of Helsinki.
There are also no ethical grounds for the device and
pharmaceutical industries’ claims of exemption on the basis
that trial registration would threaten competition or innova-
tion. The Nuremburg Code states unequivocally that human
experiments “should be such as to yield fruitful results for the
good of society”.
20 Study participants volunteer for trials
expecting to improve medical knowledge in general, not to
increase a company’s profit. Moreover, other industries have
experienced greater, not less, innovation with open disclo-
sure
21 so it could be argued that full and open registration
might contribute to the good of industry and society together.
The most recently proposed U.S. Congressional legislation on
this topic, “Enhancing Drug Safety and Innovation Act of 2007,”
affirms the broad duty to register at least late-phase trials. The
legislation requires registration of all trials except “exploratory”
trials “intended solely to assess safety or solely to evaluate
pharmacokinetics” or “to determine the feasibility of a device.”
The House of Representatives’ version of the bill (Waxman–
Markey) specifically includes the device industry in its trial
registration requirements,
22 whereas the corresponding Senate
bill (Enzi–Kennedy) does not.
23 These bills also donot specifically
require public disclosure of all registration data at the time of
registration. Registration data must be submitted not later than
14 days after the first patient is enrolled, but the bills appear to
leave open the possibility that industry, for example, could have
the choice to withhold some data items from public disclosure.
Onenotablepointaboutthebillsistheirintroductionofpenalties
for failuretoregister. This is crucialasvoluntary trialregistration
has been shown to be incomplete.
24,25
CONCLUSION
The Paxil and Vioxx scandals, among others, were only
sentinel events that revealed a structural flaw in the clinical
trials enterprise that allows for the mis-representation of trial
results from any sector, whether pharmaceutical or devices,
commercial or academic. It is this systematic lack of account-
ability to the “good of society” that is eroding public trust in
clinical trials. Whereas a global consensus has now solidified
on the importance of trial registration to counteract this
erosion, the practicalities of trial registration remain daunting.
Industry support and participation is a must, as an increasing
proportion of trials are being conducted in the private sector.
26
67 I. Sim: Trial Registration for Public Trust JGIMA balancing of ethical duties of human experimentation and
the needs of particular industries will be needed if we are to
continue strengthening the overall integrity of clinical trials
research.
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